

Tezspire[®] Prior Authorization Request Form DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#: Specialty:			
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street Address:			
Phone:			City:	State:	Zip:	
		Medication Info	rmation (required)			
Medication Name:			Strength: Dosage Form:			
Check if requesting brand			Directions for Use:			
Check if request is	erapy	_				
Clinical Information (required)						
Select the diagnosi	s below:					
Severe asthma						
Other diagnosis:			ICD-10 Code(s):			
Allergist/Immur	nologist 🛛 Pulmonol	bed by or in consultation v ogist	with one of the following	specialists:		
For severe asthma, also answer the following: Has the patient had two or more asthma exacerbations requiring systemic corticosteroids withn the past 12 months?						
□ Yes □ No If yes, list corticosteroids tried						
Has the patient had asthma-related hospitalization within the past 12 momths? I Yes No						
Has the patient tried high-dose inhaled corticosteroid (ICS) (i.e., greater than 500 mcg fluticasone propionate						
equivalent/day)? Yes No If yes, list ICS tried						
long-acting beta-2 agonist [LABA] [e.g., salmeterol], tiotropium)						
Has the patient tried one maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate/ salmeterol], Symbicort [budesonide/formoterol], Breo Ellipta [fluticasone/vilanterol]) Yes No If so, list drug tried						
Quantity limit reque						
What is the quantity requested per TREATMENT? syringe every weeks						
What is the reason for exceeding the plan limitations? Image: Titration or loading dose purposes						
 Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) 						
Requested strength/dose is not commercially available						
Other:						
Does the patient den		cal response to therapy a			s and the following below:	
 Improvement in forced expiratory volume in 1 second (FEV1) from baseline Yes I No 						
•	ments, diagnoses, symp	toms, medications tried or	failed, and/or any other i	nformation th	ne physician feels is important to	
For u						

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Tezspire_SouthDakotaMedicaid_2024February